

Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

<https://marketpublishers.com/r/H6EB04703DDEN.html>

Date: January 2016

Pages: 92

Price: US\$ 5,650.00 (Single User License)

ID: H6EB04703DDEN

Abstracts

The global human insulin market is poised to reach ~USD 39.13 billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. North America is expected to hold the largest share of the global human insulin market in 2015. Market growth of human insulin products is being propelled by growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of human insulin market. In addition, high product manufacturing costs is posing significant challenges for market growth during the forecast period.

In this report, the global human insulin market is segmented on the basis of products (human insulin biologics, insulin analogs & biosimilars, and delivery devices), drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed), drug brand (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands), delivery devices [insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes], and applications (type I diabetes & type II diabetes).

Human insulin drugs segment is expected to account for the larger share of the global human insulin market in 2015, followed by insulin delivery devices. Significant demand growth for human insulin drugs during the next five years is owing to factors such as

increasing market accessibility of generic human insulin products worldwide, rising government initiatives to support the development and commercialization of effective biosimilars, growing R&D for drug discovery & development, and rising proportion of aging population in developed countries.

Geographically, North America (comprising the U.S. and Canada) is expected to command the largest share of the global human insulin market in 2015, followed by Europe. Asia-Pacific is also poised to grow at the highest CAGR during the forecast period, owing to factors such as growing diabetes prevalence in APAC (coupled with large diabetic & pre-diabetic patient population), strengthening distribution networks of global product manufacturers in the region, evolving regulatory framework for marketing approvals & medical reimbursements, and rising public awareness related to benefits offered by human insulin in diabetes treatment (as compared to anti-diabetic drugs & animal derived insulin).

The global human insulin market is highly competitive, with various global as well as local players. In 2014, the global human insulin devices market was dominated by Sanofi (France), Novo Nordisk A/S (Denmark), and Eli Lilly and Company (U.S.), which together accounted for ~89.0% of the human insulin market. Geographic expansion, new product launches, agreements, collaborations, partnerships, awareness campaigns, and offering research fund & grants are the major strategies adopted by most market players to achieve growth in the global human insulin market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis such as market share analysis of the top ten players and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high-growth segments of the human insulin market, and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms to garner higher market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lan...

Market Penetration: Comprehensive information on the human insulin products offered by the top 10 players in the global market. The report analyzes the human insulin market by product, drug type, drug brand, delivery devices, and applications across key geographic regions

Product Development/Innovation: Detailed insights on upcoming human insulin products, product pipeline, research and development activities, and new product launches in the market

Market Development: Comprehensive information on lucrative emerging markets. The report analyzes the markets for various human insulin products across key geographic regions

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global human insulin market

Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the global human insulin market

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Key data from secondary sources
 - 2.1.2 PRIMARY DATA
 - 2.1.2.1 Key data from primary sources
 - 2.1.2.2 Breakdown of primaries
- 2.2 MARKET SIZE ESTIMATION
 - 2.2.1 BOTTOM-UP APPROACH
 - 2.2.2 TOP-DOWN APPROACH
- 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.4 RESEARCH ASSUMPTIONS
 - 2.4.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

- 3.1 INTRODUCTION
- 3.2 CURRENT MARKET SCENARIO
- 3.3 FUTURE OUTLOOK
- 3.4 CONCLUSION

4 PREMIUM INSIGHTS

- 4.1 GLOBAL HUMAN INSULIN MARKET (2015–2020)
- 4.2 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE (2015)

4.3 GLOBAL HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE
(2015-2020)

4.4 GLOBAL HUMAN INSULIN DRUGS MARKET, BY BRAND (2015 VS. 2020)

4.5 GLOBAL HUMAN INSULIN PRODUCTS MARKET SIZE, BY COUNTRY
(2015-2020)

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET SEGMENTATION

5.3 MARKET EVOLUTION

5.4 MARKET DYNAMICS

5.4.1 KEY MARKET DRIVERS

5.4.1.1 Growth in the number of diabetic patients

5.4.1.2 Rising market demand for human insulin analogs

5.4.1.3 Technological advancements in human insulin delivery devices

5.4.1.4 Favorable medical reimbursement scenario in developed countries

5.4.2 KEY MARKET RESTRAINTS

5.4.2.1 Stringent regulatory requirements for product approval

5.4.3 KEY MARKET OPPORTUNITIES

5.4.3.1 Expansion of healthcare infrastructure across Emerging markets

5.4.3.2 Expected patent expiry of key human insulin drugs

5.4.4 KEY MARKET CHALLENGE

5.4.4.1 High product manufacturing costs

6 INDUSTRY INSIGHTS

6.1 INTRODUCTION

6.2 INDUSTRY TRENDS

6.2.1 GROWING MARKET DEMAND FOR HUMAN INSULIN PENS

6.2.2 INCREASING MARKET FOCUS ON THE PIPELINE DEVELOPMENT OF
NOVEL HUMAN INSULIN THERAPIES

6.3 PIPELINE ANALYSIS

6.3.1 BY COMPANY

6.3.2 BY CLINICAL TRIAL PHASE

6.3.3 PORTER'S FIVE FORCE ANALYSIS

6.3.3.1 Threat from new entrants

6.3.3.2 Threat from substitutes

6.3.3.3 Bargaining power of buyers

- 6.3.3.4 Bargaining power of suppliers
- 6.3.3.5 Intensity of competitive rivalry

7 GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE

- 7.1 INTRODUCTION
- 7.2 HUMAN INSULIN DRUGS
- 7.3 HUMAN INSULIN DELIVERY DEVICES

8 GLOBAL HUMAN INSULIN DRUGS MARKET, BY TYPE

- 8.1 INTRODUCTION
- 8.2 INSULIN ANALOGS AND BIOSIMILARS
 - 8.2.1 LONG-ACTING
 - 8.2.2 RAPID-ACTING
 - 8.2.3 PREMIXED
- 8.3 HUMAN INSULIN BIOLOGICS
 - 8.3.1 SHORT-ACTING
 - 8.3.2 INTERMEDIATE-ACTING
 - 8.3.3 PREMIXED

9 GLOBAL HUMAN INSULIN DRUGS MARKET, BY BRAND

- 9.1 INTRODUCTION
- 9.2 INSULIN ANALOGS AND BIOSIMILARS
 - 9.2.1 LANTUS
 - 9.2.2 NOVORAPID AND NOVOLOG
 - 9.2.3 HUMALOG
 - 9.2.4 OTHER BRANDS
- 9.3 HUMAN INSULIN BIOLOGICS
 - 9.3.1 ACTRAPID, MIXTARD, AND INSULATARD
 - 9.3.2 HUMULIN
 - 9.3.3 INSUMAN

10 GLOBAL HUMAN INSULIN MARKET, BY DELIVERY DEVICE

- 10.1 INTRODUCTION
- 10.2 HUMAN INSULIN PENS
 - 10.2.1 REUSABLE PENS

- 10.2.2 DISPOSABLE PENS
- 10.3 HUMAN INSULIN PEN NEEDLES
 - 10.3.1 STANDARD PEN NEEDLES
 - 10.3.2 SAFETY PEN NEEDLES
- 10.4 HUMAN INSULIN SYRINGES

11 GLOBAL HUMAN INSULIN MARKET, BY APPLICATION

- 11.1 INTRODUCTION
- 11.2 TYPE I DIABETES
- 11.3 TYPE II DIABETES

12 HUMAN INSULIN MARKET, BY REGION

- 12.1 INTRODUCTION
- 12.2 NORTH AMERICA
 - 12.2.1 U.S.
 - 12.2.2 CANADA
- 12.3 EUROPE
 - 12.3.1 GERMANY
 - 12.3.2 FRANCE
 - 12.3.3 U.K.
 - 12.3.4 REST OF EUROPE (ROE)
- 12.4 ASIA-PACIFIC (APAC)
 - 12.4.1 JAPAN
 - 12.4.2 CHINA
 - 12.4.3 INDIA
 - 12.4.4 REST OF ASIA-PACIFIC (ROAPAC)
- 12.5 REST OF THE WORLD (ROW)

13 COMPETITIVE LANDSCAPE

- 13.1 OVERVIEW
- 13.2 MARKET SHARE ANALYSIS
 - 13.2.1 HUMAN INSULIN DRUGS MARKET
 - 13.2.2 HUMAN INSULIN DELIVERY DEVICES MARKET
- 13.3 COMPETITIVE SCENARIO
- 13.4 RECENT DEVELOPMENTS
 - 13.4.1 GEOGRAPHICAL EXPANSIONS

- 13.4.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
- 13.4.3 NEW PRODUCT LAUNCHES
- 13.4.4 AWARENESS PROGRAMS
- 13.4.5 FUNDING & SCHOLARSHIPS
- 13.4.6 STRATEGIC ACQUISITIONS

14 COMPANY PROFILES

(Overview, Financials, Products & Services, Strategy, & Developments)*

- 14.1 INTRODUCTION
- 14.2 B. BRAUN MELSUNGEN AG
- 14.3 BECTON, DICKINSON AND COMPANY
- 14.4 BIOCON LIMITED
- 14.5 BIODEL INC.
- 14.6 ELI LILLY AND COMPANY
- 14.7 JULPHAR (ALSO KNOWN AS GULF PHARMACEUTICAL INDUSTRIES)
- 14.8 NOVO NORDISK A/S
- 14.9 SANOFI
- 14.10 WOCKHARDT LIMITED
- 14.11 YPSOMED AG

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

15 APPENDIX

- 15.1 INSIGHTS OF INDUSTRY EXPERTS
- 15.2 DISCUSSION GUIDE
- 15.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
- 15.4 AVAILABLE CUSTOMIZATIONS
- 15.5 RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1 KEY HUMAN INSULIN DRUGS: YEAR OF PATENT EXPIRY

Table 2 KEY HUMAN INSULIN THERAPIES UNDER PIPELINE DEVELOPMENT & COMMERCIALIZATION: 2005-2015

Table 3 HUMAN INSULIN PIPELINE: MAJOR COMPANIES INVOLVED

Table 4 HUMAN INSULIN PIPELINE: STAGES OF CLINICAL TRIAL

Table 5 GLOBAL HUMAN INSULIN MARKET SIZE, BY PRODUCT TYPE, 2013–2020 (USD MILLION)

Table 6 HUMAN INSULIN DRUGS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 7 HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 8 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)

Table 9 GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)

Table 10 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 11 LONG-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 12 RAPID-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 13 PREMIXED INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 14 GLOBAL HUMAN INSULIN BIOLOGICS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)

Table 15 HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 16 SHORT-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 17 INTERMEDIATE-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 18 PREMIXED HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 19 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2013–2020 (USD MILLION)

Table 20 GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY BRAND, 2013–2020 (USD MILLION)

Table 21 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 22 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR LANTUS, BY REGION, 2013–2020 (USD MILLION)

Table 23 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR NOVORAPID AND NOVOLOG, BY REGION, 2013–2020 (USD MILLION)

Table 24 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR HUMALOG, BY REGION, 2013–2020 (USD MILLION)

Table 25 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR OTHER BRANDS, BY REGION, 2013–2020 (USD MILLION)

Table 26 GLOBAL HUMAN INSULIN BIOLOGICS MARKET SIZE, BY BRAND, 2013–2020 (USD MILLION)

Table 27 HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 28 HUMAN INSULIN BIOLOGICS MARKET SIZE FOR ACTRAPID, MIXTARD, AND INSULATARD, BY REGION, 2013–2020 (USD MILLION)

Table 29 HUMAN INSULIN BIOLOGICS MARKET SIZE FOR HUMULIN, BY REGION, 2013–2020 (USD MILLION)

Table 30 HUMAN INSULIN BIOLOGICS MARKET SIZE FOR INSUMAN, BY REGION, 2013–2020 (USD MILLION)

Table 31 GLOBAL HUMAN INSULIN MARKET SIZE, BY DELIVERY DEVICE, 2013–2020 (USD MILLION)

Table 32 GLOBAL HUMAN INSULIN PENS MARKET SIZE, BY PRODUCT TYPE, 2013–2020 (USD MILLION)

Table 33 HUMAN INSULIN PENS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 34 REUSABLE HUMAN INSULIN PENS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 35 DISPOSABLE HUMAN INSULIN PENS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 36 GLOBAL HUMAN INSULIN PEN NEEDLES MARKET SIZE, BY PRODUCT TYPE, 2013–2020 (USD MILLION)

Table 37 HUMAN INSULIN PEN NEEDLES MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 38 HUMAN INSULIN STANDARD PEN NEEDLES MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 39 HUMAN INSULIN SAFETY PEN NEEDLES MARKET SIZE, BY REGION,

2013–2020 (USD MILLION)

Table 40 HUMAN INSULIN SYRINGES MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 41 HUMAN INSULIN MARKET SIZE, BY REGION, 2013–2020 (USD MILLION)

Table 42 NORTH AMERICA: HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)

Table 43 NORTH AMERICA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 44 NORTH AMERICA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 45 NORTH AMERICA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 46 U.S.: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 47 U.S.: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 48 U.S.: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 49 CANADA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 50 CANADA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 51 CANADA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 52 EUROPE: HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)

Table 53 EUROPE: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 54 EUROPE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 55 EUROPE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 56 GERMANY: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 57 GERMANY: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 58 GERMANY: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 59 FRANCE: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020

(USD MILLION)

Table 60 FRANCE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 61 FRANCE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 62 U.K.: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 63 U.K.: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 64 U.K.: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 65 ROE: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 66 ROE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 67 ROE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 68 APAC: HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)

Table 69 APAC: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 70 APAC: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 71 APAC: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 72 JAPAN: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 73 JAPAN: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 74 JAPAN: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 75 CHINA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 76 CHINA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 77 CHINA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 78 INDIA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 79 INDIA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 80 INDIA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 81 ROAPAC: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 82 ROAPAC: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 83 ROAPAC: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 84 ROW: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 85 ROW: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 86 ROW: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION)

Table 87 GEOGRAPHICAL EXPANSIONS, 2012–2015

Table 88 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2012–2015

Table 89 NEW PRODUCT LAUNCHES AND PRODUCT APPROVALS, 2012–2015

Table 90 AWARENESS PROGRAMS, 2012–2015

Table 91 FUNDING & SCHOLARSHIPS, 2012–2015

Table 92 STRATEGIC ACQUISITIONS, 2012–2015

List Of Figures

LIST OF FIGURES

Figure 1 RESEARCH DESIGN

Figure 2 BOTTOM-UP APPROACH

Figure 3 TOP-DOWN APPROACH

Figure 4 DATA TRIANGULATION

Figure 5 ASSUMPTIONS FOR THE RESEARCH STUDY

Figure 6 HUMAN INSULIN MARKET SHARE, BY KEY PLAYER, 2014

Figure 7 FUTURE TRENDS: HUMAN INSULIN MARKET SIZE, BY PRODUCT
(2015–2020)

Figure 8 FUTURE TRENDS: HUMAN INSULIN DRUGS MARKET SHARE, BY TYPE
(2015 VS. 2020)

Figure 9 FUTURE TRENDS: HUMAN INSULIN DRUGS MARKET SIZE, BY BRAND
(2015–2020)

Figure 10 FUTURE TRENDS: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE,
BY PRODUCT TYPE (2015–2020)

Figure 11 FUTURE TRENDS: HUMAN INSULIN MARKET SHARE, BY REGION (2015)

Figure 12 ATTRACTIVE GROWTH OPPORTUNITIES IN THE HUMAN INSULIN
MARKET

Figure 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE HUMAN INSULIN
MARKET IN 2015

Figure 14 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF ALL
SEGMENTS OF THE HUMAN INSULIN DELIVERY DEVICES MARKET IN 2015

Figure 15 LANTUS IS EXPECTED TO BE THE LEADING INSULIN ANALOG TILL
2020

Figure 16 CHINA AND INDIA TO LEAD THE MARKET DEMAND FOR HUMAN
INSULIN PRODUCTS DURING THE FORECAST PERIOD

Figure 17 MARKET EVOLUTION OF HUMAN INSULIN PRODUCTS

Figure 18 HUMAN INSULIN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, &
CHALLENGES

Figure 19 GROWTH IN DIABETIC PATIENT POPULATION ACROSS KEY WHO
REGIONS (2000–2030)

Figure 20 PROPORTION OF GERIATRIC POPULATION, BY COUNTRY (2012 VS.
2020)

Figure 21 GLOBAL TREND IN GOVERNMENT HEALTHCARE EXPENDITURE:
DEVELOPED VS. DEVELOPING COUNTRIES (2010–2012)

Figure 22 PORTER'S FIVE FORCES ANALYSIS (2014): INCREASING NUMBER OF

NEW PRODUCT MANUFACTURERS INCREASES MARKET COMPETITION
Figure 23 DELIVERY DEVICES POISED TO GROW AT THE HIGHEST RATE
DURING 2015-2020

Figure 24 U.S. & EUROPE LEAD GLOBALLY, IN TERMS OF THE NUMBER OF
ONGOING HUMAN INSULIN-BASED CLINICAL STUDIES (2015)

Figure 25 LONG-ACTING DRUGS TO LEAD THE INSULIN ANALOGS AND
BIOSIMILARS MARKET TILL 2020

Figure 26 ASIA-PACIFIC IS POISED TO BE THE FASTEST GROWING MARKET FOR
LONG-ACTING INSULIN ANALOGS AND BIOSIMILAR PRODUCTS DURING
FORECAST PERIOD

Figure 27 INTERMEDIATE-ACTING DRUGS WILL CONTINUE TO DOMINATE THE
HUMAN INSULIN BIOLOGICS MARKET TILL 2020

Figure 28 NORTH AMERICA IS EXPECTED TO DOMINATE THE INTERMEDIATE-
ACTING HUMAN INSULIN BIOLOGICS MARKET DURING THE STUDY PERIOD

Figure 29 INSULIN ANALOGS & BIOSIMILAR DRUGS POISED TO GROW AT THE
FASTEST RATE

Figure 30 LANTUS EXPECTED TO HOLD THE LARGEST SHARE OF INSULIN
ANALOGS & BIOSIMILAR BRANDS MARKET TILL 2020

Figure 31 ASIA-PACIFIC POISED TO BE THE FASTEST-GROWING MARKET FOR
NOVORAPID DURING THE FORECAST PERIOD

Figure 32 HUMULIN IS POISED TO BE THE FASTEST-GROWING HUMAN INSULIN
BIOLOGICS BRANDS DURING 2015-2020

Figure 33 INSULIN PENS TO DOMINATE THE HUMAN INSULIN DELIVERY
DEVICES MARKET DURING THE FORECAST PERIOD (2015–2020)

Figure 34 APAC TO DOMINATE THE HUMAN INSULIN PEN NEEDLES MARKET BY
2020

Figure 35 INDIA WILL HAVE THE HIGHEST DIABETES POPULATION BY 2030

Figure 36 MARKET TRENDS: NORTH AMERICAN HUMAN INSULIN MARKET
(2015-2020)

Figure 37 MARKET TRENDS: EUROPEAN HUMAN INSULIN MARKET (2015-2020)

Figure 38 ASIA-PACIFIC HUMAN INSULIN MARKET SNAPSHOT, 2015-2020

Figure 39 LEADING PLAYERS ADOPTED THE STRATEGY OF GEOGRAPHIC
EXPANSIONS TO STRENGTHEN THEIR MARKET POSITIONING DURING 2012 TO
2015

Figure 40 GLOBAL HUMAN INSULIN MARKET SHARE, BY KEY PLAYER (2014)

Figure 41 GLOBAL HUMAN INSULIN DRUGS MARKET RANKING, BY KEY PLAYER
(2014)

Figure 42 GLOBAL HUMAN INSULIN DELIVERY DEVICES MARKET RANKING, BY
KEY PLAYER (2014)

Figure 43 CONTINUOUS GEOGRAPHIC EXPANSION IS STIMULATING MARKET COMPETITION FOR CAPACITY BUILDING AMONG KEY PLAYERS

Figure 44 GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS (2014)

Figure 45 LEADING COMPANIES ARE FOCUSING ON CAPACITY BUILDING TO STRENGTHEN THEIR PRODUCT DEVELOPMENT & MANUFACTURING BASE

Figure 46 LEADING HUMAN INSULIN MANUFACTURERS ARE FOCUSING ON PRODUCT COMMERCIALIZATION TO STRENGTHEN THEIR MARKET POSITION

Figure 47 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT

Figure 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT

Figure 49 BIOCON LIMITED: COMPANY SNAPSHOT

Figure 50 ELI LILLY AND COMPANY: COMPANY SNAPSHOT

Figure 51 JULPHAR: COMPANY SNAPSHOT

Figure 52 NOVO NORDISK A/S: COMPANY SNAPSHOT

Figure 53 SANOFI: COMPANY SNAPSHOT

Figure 54 WOCKHARDT LIMITED: COMPANY SNAPSHOT

Figure 55 YPSOMED AG: COMPANY SNAPSHOT

I would like to order

Product name: Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

Product link: <https://marketpublishers.com/r/H6EB04703DDEN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H6EB04703DDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970